All lobbying filings

STEPTOE LLP

STEPTOE LLP filed a Q1 report for OREXO US, INC. on April 19, 2026, reporting $230,000 in lobbying income.

Lobbying for OREXO US, INC. · Pharmaceuticals / health products

All filings by STEPTOE LLP · Everything OREXO US, INC. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 19, 2026

Income

$230,000

What the client paid this registrant for the period.

Client based in

New Jersey

Official filing document

Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Alcohol and Drug Abuse

Advocacy on xylazine and adultered-opioid overdose solutions and federal funding.

Budget/Appropriations

Advocacy on xylazine and adultered-opioid overdose solutions and federal funding.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.